PuraMed BioScience, Inc. Outlines 2012 Marketing Plans for Clinically Tested Migraine Treatment LipiGesic(R) M

SCHOFIELD, Wis., Dec. 21, 2011 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today, an outline of its plans for the national product launch of its clinically tested migraine treatment LipiGesic(R) M.

The Company has always emphasized science as the key to their success and this year three of the top headache researchers in the United States conducted a Double-blind, Placebo controlled, clinical trial of LipiGesic(R) M. The study was peer reviewed and published in the top-tier medical journal Headache Volume 51, Number 7, July/August 2011. The study demonstrated that the product was safe, highly effective and is recommended as a First Line treatment (the primary or first treatment to try) for migraine headaches, to the medical community.

The President and CEO, Russ Mitchell stated: "Once the study was published, we moved forward by using the published clinical data to foster our partnerships with the two largest retail chain drug stores in the USA, Walgreens and CVS. We expect to continue to build upon these relationships and anticipate finalizing sales purchase order agreements with more chain drug and mass market outlets to provide easy product access to all migraine sufferers. Our next step is to educate the medical community and healthcare professionals so they become greater aware of LipiGesic(R) M."

Knowing that direct contact, clinical study information distribution and sampling opportunities bring the best results, the Company has begun to reserve attendance to 2012 Medical Conferences and Continued Medical Education (CME's) events held for all healthcare professionals that have migraine patients in their practices, including: Neurologists, General Practitioners, Pharmacists, Physician Assistants, Nurse Practitioners, Nurses and Chiropractors.

PuraMed has developed a "Doctor Detailing Kit" that is currently being sent directly to health professionals, across the country that include samples, study data and use indications to inform Doctors who are unable to attend the various conferences throughout the year.

Consumer advertising will begin by both testimonial and information based newspaper, magazine, radio and cable television ads. These will all be coordinated with PuraMed's retail partners and will include special coupons and promotions to help initially drive customers to the stores.

PuraMed will continue to explore various options to enhance their presence on the Internet and social media sites in 2012. The Company also recently launched its updated LipiGesic(R) M website located at http://www.lipigesic.com/ and its corporate website: http://www.puramedbioscience.com/ as well as established its Social Networking sites in Twitter, Facebook and Google Plus. The Company has already begun to obtain many migraine followers and they are increasing daily as more people are driven to these sites.

The Company plans to continue its research efforts in 2012. PuraMed already has established its protocol, identified researchers, and selected sites for a new Double Blind Placebo Controlled study of LipiGesic M for the potential use with children. There are nearly 2 million children in the USA that suffer from frequent debilitating migraines with no prescription treatments approved for use on children. Medical professionals will not recommend any of the adult approved treatments because they have concerns of side effect profiles. Children were included in the LipiGesic M study, published earlier this year and the encouraging efficacy and safety results have paved the way to study a larger population. This study will commence in early 2012.

About PuraMed BioScience, Inc.:

PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract. LipiGesic M has national distribution and is available nationwide in Walgreens and soon CVS chain drug stores in the United States. In addition to LipiGesic M, the Company also has plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM which provides a remedy for insomnia and other sleep disorders.

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

For more information, contact:
Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
715-359-6373
[email protected]
Website: www.PuramedBioScience.com

Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy, 847-945-2222
Website: www.investorawareness.com

Media Contact:
North Shore Public Relations, Inc.
Tony Schor, 847-945-4505
Website: www.northshorepr.com

SOURCE PuraMed BioScience, Inc.